AstraZeneca's antibody drug over 80% effective at preventing Covid, trial shows

The data showed that patients given a single injection of the antibody treatment were 83% less likely to develop symptomatic cases of the coronavirus than participants who were given a placebo. Around 2% of the world’s population is thought to be at risk of not responding well to Covid-19 vaccines, according to AstraZeneca. In a separate trial, patients with mild-to-moderate Covid-19 who were given one dose of AZD7442 within three days of developing symptoms had their risk of developing severe disease reduced by 88%.